Skip to main content

iSUN3D

ServiceShenzhen, China (Headquarters), Wuhan, China (Flexible Manufacturing Center)Founded 2002· One of 2247 Service companies tracked by AMPulse

A comprehensive digital orthotic solution provider specializing in 3D-printed custom insoles and footwear through an integrated 'scanning-design-printing' ecosystem.

CEO / Founder
Kevin Yang (杨义浒)
Team Size
51-200
Stage
Active
Total Funding
$35.5M
Latest Round
Post-IPO
Key Investors
SCGC (深创投), HTI Group, Guangdong Hongtu Technology

Technology & Products

Key Products

3D-printed custom insoles and footwear, FlexOne series high-speed resin printers, single-component elastomers.

Technological Advantage

Proprietary single-component elastomers capable of 20 MPa tensile strength and over 1,000,000 flex cycles, combined with a vertically integrated supply chain inherited from parent company eSUN.

Differentiation

Value Proposition

Replaces traditional, labor-intensive manual molding with a fully digital workflow that enables mass-customization of high-performance, durable orthotics with significantly reduced lead times.

How They Differentiate

Vertical integration through parent company eSUN, combining proprietary high-performance flexible materials (TPU/Resins) with a centralized 'Service + Platform' manufacturing model that utilizes high-speed resin printing for mass customization.

Market & Competition

Target Customers

Orthopedic clinics, rehabilitation centers, hospitals, professional athletes, and global footwear brands.

Industry Verticals

Medical & Healthcare (Orthopedics), Rehabilitation Medicine, Footwear & Apparel, Sports Science, Additive Manufacturing

Competitors

Materialise (Phits); Aetrex; Voxelcare; FitMyFoot

Growth & Milestones

Growth Metrics

Operating a global network of 200+ clinics; aiming for 1,000+ high-speed printers by 2026 at the Wuhan center.

Major Milestones

Parent company Shenzhen eSUN Industrial Co., Ltd. listed on NEEQ in 2016, Launched the first generation iSUN3D FLX insole printer in 2018, Released the FlexOne high-speed resin printing system in 2023, Opened the Wuhan Flexible Manufacturing Center in 2024 to scale mass-customization capacity

Notable Customers

Wuhan Union Hospital; Global Footwear Brands (OEM/ODM); 200+ Orthopedic Clinics globally; Pedcad Foot Technology GmbH (exclusive distributor in Germany for iSUN3D-FLX2 insoles printer)

https://www.isun3d.net

Recent coverage of iSUN3D

Why this company matters

AMPulse analysis, not a company disclosure

iSUN3D has transitioned from a hardware and materials vendor into a service-and-platform model for digital orthotics. By replacing manual plaster casting with an integrated scanning-design-printing workflow, the company enables mass customization of insoles and footwear at reduced lead times. Its Wuhan Flexible Manufacturing Center, opened in 2024, serves as a centralized production hub for a global network of over 200 clinics.

The company's core technology stack includes polymer material extrusion and vat photopolymerization (DLP), with a focus on high-speed resin printing via the FlexOne series. Proprietary single-component elastomers achieve 20 MPa tensile strength and exceed 1,000,000 flex cycles, targeting the durability requirements of medical and athletic orthotics. This material capability is inherited from parent company eSUN, a global supplier of biodegradable 3D printing filaments.

iSUN3D's target customers include orthopedic clinics, rehabilitation centers, hospitals, and footwear brands. Notable partners include Wuhan Union Hospital and Pedcad Foot Technology GmbH, which serves as the exclusive German distributor for the iSUN3D-FLX2 insole printer. The company also operates an OEM/ODM channel for global footwear brands. Competitors in the digital orthotics space include Materialise (Phits), Aetrex, Voxelcare, and FitMyFoot.

Vertical integration through eSUN provides iSUN3D with a defensible cost and R&D advantage in materials, while the centralized manufacturing model reduces per-unit cost for clinics that would otherwise need in-house printing equipment. The company has raised $35.5 million from investors including Shenzhen Capital Group and Guangdong Hongtu Technology. A stated goal of deploying over 1,000 high-speed printers at the Wuhan center by 2026 signals an aggressive scale-up, though execution risk remains in aligning clinic adoption with production capacity.